Paid Clinical Trials - 82,000 Members & Growing

  • Paid Clinical Trials
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.

Sponsored Links







  • Conditions:   Malignant Rhabdoid Tumor;   Atypical Teratoid Rhabdoid Tumor
    Interventions:   Drug: alisertib;   Drug: methotrexate;   Drug: cisplatin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: topotecan;   Drug: vincristine;   Procedure: Surgical resection;   Radiation: Radiation therapy
    Sponsors:   St. Jude Children's Research Hospital;   Millennium Pharmaceuticals, Inc.
    Not yet recruiting - verified April 2014

  • Conditions:   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: bortezomib;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: daunorubicin hydrochloride;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: mercaptopurine tablet;   Drug: doxorubicin hydrochloride;   Drug: thioguanine;   Drug: hydrocortisone sodium succinate;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: etoposide;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting - verified April 2014

  • Condition:   Metastatic Cancer That Express the MAGE-A3-DP4 Antigen
    Interventions:   Genetic: Anti-MAGE-A3-DP4 TCR PBL;   Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Radiotherapy
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Melanoma;   Skin Cancer
    Interventions:   Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cylcophosphamide;   Genetic: 41BB Selected Tumor Infiltrating Lymphocytes
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: dexamethasone;   Drug: vincristine sulfate;   Drug: pegaspargase;   Drug: mitoxantrone hydrochloride;   Drug: methotrexate;   Drug: therapeutic hydrocortisone;   Drug: cytarabine;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: asparaginase;   Procedure: allogeneic hematopoietic stem cell transplantation;   Biological: blinatumomab;   Drug: mercaptopurine tablet;   Drug: thioguanine;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2014

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: etoposide;   Drug: cyclophosphamide;   Radiation: total marrow irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2014

  • Conditions:   Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
    Interventions:   Drug: Simvastatin;   Drug: Doxorubicin/cyclophosphamide
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Not yet recruiting - verified March 2014

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2014

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
    Sponsors:   New York Medical College;   St. Baldrick's Foundation
    Recruiting - verified March 2014

  • Conditions:   Lupus Erythematosus;   Graft-versus-host Disease
    Interventions:   Drug: Cyclophosphamide;   Drug: Sodium-2-mercapto ethane sulphonate;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mofetil;   Drug: Rabbit antithymocyte globulin
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Not yet recruiting - verified March 2014

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: carfilzomib;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2014

  • Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL;   Biological: dendritic cell vaccine therapy;   Biological: aldesleukin;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2014

  • Conditions:   Metastatic Cancer;   Metastatic Melanoma
    Interventions:   Genetic: Anti-ESO TCR transduced CD62L+ lymph;   Drug: aldesleukin;   Drug: cyclophosphamide;   Drug: fludarabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2014

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine
    Sponsors:   Columbia University;   Diane George, MD
    Recruiting - verified February 2014

  • Conditions:   Adult Liposarcoma;   Adult Synovial Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Drug: cyclophosphamide;   Biological: NY-ESO-1-specific T cells;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2014

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: busulfan;   Drug: fludarabine phosphate;   Radiation: total-body irradiation (TBI);   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclophosphamide
    Sponsor:   Washington University School of Medicine
    Not yet recruiting - verified March 2014

  • Conditions:   Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
    Interventions:   Biological: H1299 Lysate Vaccine;   Drug: Cyclophosphamide;   Drug: Celecoxib
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
    Interventions:   Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: Tecemotide;   Drug: Placebo;   Drug: Cyclophosphamide (CPA);   Drug: Saline (sodium chloride)
    Sponsor:   EMD Serono
    Recruiting - verified March 2014

  • Conditions:   Acute Lymphocytic Leukemia;   Adult Lymphoblastic Lymphoma
    Interventions:   Drug: DNR;   Drug: VCR;   Drug: PEG-asp;   Drug: CTX;   Drug: Prednisone;   Drug: Liposomal AraC;   Drug: MTX;   Drug: LCV;   Drug: AraC;   Drug: Etoposide;   Drug: Dasatinib;   Drug: Rituximab;   Drug: Hydrocortisone
    Sponsors:   University of California, San Diego;   Sigma Tau Pharmaceuticals, Inc.
    Recruiting - verified January 2014

  • Condition:   Neuroblastoma
    Interventions:   Drug: DFMO;   Drug: Celecoxib;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Procedure: CD8+ T Cells;   Drug: Interleukin-2;   Drug: Ipilimumab
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Institute of Texas (CPRIT);   American Association for Cancer Research
    Not yet recruiting - verified March 2014

  • Condition:   Kidney Transplantation
    Interventions:   Biological: Antithymocyte globulin (ATG);   Drug: Fludarabine;   Drug: Low dose Pre-transplant cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Methylprednisolone;   Biological: Bone Marrow;   Drug: MESNA;   Drug: Mycophenolate mofetil (MMF);   Drug: Prednisone;   Drug: Filgrastim;   Drug: High dose post-transplant cyclophosphamide
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting - verified January 2014

  • Conditions:   Leukemia;   Lymphoma;   MDS
    Intervention:   Drug: Conditioning Regimen & GVHD Prophylaxis
    Sponsor:   Ann & Robert H Lurie Children's Hospital of Chicago
    Recruiting - verified January 2014

  • Condition:   Untreated Childhood Medulloblastoma
    Interventions:   Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: methotrexate;   Drug: etoposide;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Procedure: cognitive assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Triple Negative Breast Cancer
    Interventions:   Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsor:   AbbVie
    Recruiting - verified January 2014

  • Conditions:   Recurrent or Refractory Solid Tumors;   Ewing Sarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Osteosarcoma
    Intervention:   Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
    Sponsors:   Merrimack Pharmaceuticals;   South Plains Oncology Consortium (SPOC)
    Recruiting - verified January 2014

  • Condition:   Sickle Cell Disease
    Interventions:   Procedure: Haploidentical Transplant;   Drug: Alemtuzumab;   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Sirolimus
    Sponsors:   University of Illinois at Chicago;   Damiano Rondelli, MD
    Recruiting - verified January 2014

  • Condition:   Breast Cancer
    Interventions:   Biological: DC vaccination+Preop chemotherapy;   Biological: DC vaccination+Preop chemo+anakinra
    Sponsor:   Baylor Research Institute
    Not yet recruiting - verified December 2013

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: methotrexate;   Drug: pegaspargase;   Drug: cyclophosphamide;   Drug: mercaptopurine tablet;   Biological: blinatumomab;   Drug: etoposide;   Drug: prednisone;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young Tumor Infiltrating Lymphocytes (young TIL)
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified October 2013

  • Conditions:   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Extracranial Germ Cell Tumor;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Malignant Ovarian Germ Cell Tumor;   Childhood Malignant Testicular Germ Cell Tumor;   Childhood Medulloepithelioma;   Childhood Supratentorial Ependymoma;   Childhood Teratoma;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pilomyxoid Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Retinoblastoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Drug: etoposide;   Drug: ifosfamide;   Drug: carboplatin;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: cisplatin;   Biological: filgrastim;   Other: laboratory biomarker analysis
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI);   Children's Hospital of Michigan
    Recruiting - verified November 2013

  • Condition:   Breast Cancer Stages I Through III
    Interventions:   Device: Acupuncture;   Other: No Acupuncture- Standard of Care
    Sponsor:   OhioHealth
    Recruiting - verified December 2013

  • Condition:   Hematopoietic/Lymphoid Cancer
    Interventions:   Radiation: Total-Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified November 2013

  • Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Severe Aplastic Anemia;   Allogeneic Transplant
    Intervention:   Drug: Cyclophosphamide
    Sponsors:   University of Alabama at Birmingham;   Racquel Innis-Shelton, MD
    Recruiting - verified February 2014

  • Conditions:   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
    Interventions:   Drug: brentuximab vedotin;   Drug: crizotinib;   Drug: dexamethasone;   Drug: ifosfamide;   Drug: methotrexate;   Drug: cytarabine;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Onyx Pharmaceuticals;   Onyx Therapeutics, Inc.
    Recruiting - verified March 2014

  • Condition:   Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PCI-32765 (Ibrutinib);   Drug: Placebo
    Sponsors:   Janssen Research & Development, LLC;   Pharmacyclics
    Recruiting - verified April 2014

  • Condition:   Lymphoma, B-Cell, Non-Hodgkin's Lymphoma
    Interventions:   Drug: DCDS4501A;   Drug: rituximab [MabThera/Rituxan];   Drug: cyclophosphamide;   Drug: prednisone;   Drug: doxorubicin
    Sponsor:   Genentech
    Recruiting - verified April 2014

  • Condition:   2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
    Interventions:   Biological: GVAX Pancreas Vaccine;   Biological: CRS-207;   Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib;   Drug: cyclophosphamide
    Sponsor:   Aduro BioTech, Inc.
    Recruiting - verified March 2014

  • Conditions:   Metastatic Cancers Other Than Melanoma That Express ESO Antigen;   Synovial Sarcoma;   Esophageal;   Heaptoma;   Breast;   Malignant Menigioma
    Interventions:   Genetic: Anti-NY ESO-1 mTCR PBL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Condition:   Metastatic Beast Cancer
    Interventions:   Drug: Exemestane;   Drug: Cyclophosphamide
    Sponsor:   New York University School of Medicine
    Recruiting - verified October 2013

  • Condition:   Metastatic Colorectal Cancer
    Interventions:   Drug: CY;   Biological: GVAX;   Drug: SGI-110
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Not yet recruiting - verified October 2013

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Large Cell Non-Hodgkin Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified October 2013

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: busulfan;   Drug: etoposide;   Drug: cyclophosphamide;   Procedure: peripheral blood stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Multiple Myeloma in Relapse;   Refractory Plasma Cell Neoplasm
    Interventions:   Drug: LCL161;   Drug: cyclophosphamide
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   CPRIT
    Not yet recruiting - verified March 2014

  • Conditions:   Desmoplastic Small Round Cell Tumor;   Ewing Sarcoma of Bone;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    Interventions:   Drug: vincristine;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: temozolomide;   Drug: temsirolimus;   Drug: bevacizumab;   Drug: sorafenib;   Procedure: surgery;   Radiation: radiation
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified November 2013

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Radiation: stereotactic body radiation therapy;   Drug: cyclophosphamide;   Biological: therapeutic autologous lymphocytes;   Other: laboratory biomarker analysis
    Sponsors:   Stanford University;   National Cancer Institute (NCI)
    Not yet recruiting - verified September 2013

  • Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Biological: trastuzumab;   Biological: bevacizumab;   Drug: docetaxel;   Drug: carboplatin;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Conditions:   Lymphoma, B-cell;   Lymphoma, Large B-cell, Diffuse
    Interventions:   Drug: brentuximab vedotin;   Drug: brentuximab vedotin;   Drug: rituximab;   Drug: vincristine;   Drug: cyclophosphamide;   Drug: prednisone;   Drug: doxorubicin
    Sponsor:   Seattle Genetics, Inc.
    Recruiting - verified March 2014

  • Conditions:   Breast Cancer;   Adenocarcinoma of the Breast
    Interventions:   Radiation: PBI;   Other: PBI with chemotherapy
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Not yet recruiting - verified August 2013

  • Condition:   Leukemia
    Interventions:   Drug: Daunorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PEG-Asparaginase;   Drug: Methotrexate;   Drug: 6-MP (6-Mercaptopurine);   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Leucovorin;   Drug: Dexamethasone
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Sigma-Tau Research, Inc.;   Duke University;   Weill Medical College of Cornell University
    Recruiting - verified March 2014

  • Conditions:   Stage II Childhood Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
    Interventions:   Drug: brentuximab vedotin;   Drug: etoposide;   Drug: prednisone;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: Dacarbazine(R);   Drug: filgrastim;   Procedure: quality of life assessment;   Radiation: radiation therapy
    Sponsors:   St. Jude Children's Research Hospital;   Seattle Genetics, Inc.
    Recruiting - verified January 2014

  • Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: Cyclophosphamide;   Biological: DRibble vaccine;   Drug: Imiquimod;   Drug: GM-CSF;   Biological: HPV vaccine
    Sponsors:   UbiVac;   National Cancer Institute (NCI);   Providence Cancer Center, Earle A. Chiles Research Institute;   Providence Health & Services;   Mayo Clinic
    Recruiting - verified July 2013

  • Conditions:   Leukemia;   Myeloproliferative Diseases
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Procedure: Expanded NK Cell Infusion;   Procedure: Bone Marrow Transplant;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Not yet recruiting - verified February 2014

  • Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: paclitaxel;   Biological: trastuzumab;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   National Cancer Institute (NCI)
    Recruiting - verified July 2013

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Cytokine-induced killer cells;   Biological: Aldesleukin
    Sponsor:   Washington University School of Medicine
    Not yet recruiting - verified April 2014

  • Conditions:   Glioblastoma;   Gliosarcoma
    Interventions:   Drug: ERC1671;   Drug: GM-CSF;   Drug: Cyclophosphamide;   Drug: Oral Control (Sucrose pill);   Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%));   Drug: Bevacizumab
    Sponsors:   University of California, Irvine;   Daniela A. Bota;   Epitopoietic Research Corporation
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Oprozomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Cyclophosphamide
    Sponsors:   Onyx Pharmaceuticals;   Onyx Therapeutics, Inc.
    Recruiting - verified February 2014

  • Condition:   Medulloblastoma
    Interventions:   Radiation: Craniospinal Irradiation with boost to the primary tumor site;   Drug: Cyclophosphamide;   Drug: Cisplatin;   Drug: Vincristine;   Drug: Vismodegib;   Drug: Pemetrexed;   Drug: Gemcitabine;   Other: Aerobic Training;   Other: Neurocognitive Remediation
    Sponsors:   St. Jude Children's Research Hospital;   Genentech
    Recruiting - verified November 2013

  • Conditions:   HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: lapatinib ditosylate;   Biological: trastuzumab;   Other: laboratory biomarker analysis
    Sponsors:   University of Southern California;   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Condition:   Malignant Neoplasm
    Interventions:   Radiation: Total-body irradiation;   Biological: Donor lymphocytes infusion (DLI);   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified December 2013

  • Condition:   Rhabdomyosarcoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Procedure: Surgical Resection;   Procedure: Radiation;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Myeloid Growth Factor;   Procedure: Lymph Node Sampling
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified December 2013

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: ixazomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: quality-of-life assessment
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   Newly Diagnosed Ewing Sarcoma
    Interventions:   Drug: Cyclophosphamide;   Device: Doxorubicin;   Drug: Vincristine;   Device: Ifosfamide;   Drug: Etoposide;   Procedure: Surgery;   Radiation: Radiation Therapy*
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified March 2014

  • Conditions:   GATA2;   Immunodeficiency;   MDS
    Interventions:   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Equine Anti-Thymocyte Globulin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   Hodgkin Disease
    Interventions:   Drug: ABVE-PC;   Drug: DECA
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified April 2014

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer
    Recruiting - verified January 2014

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: lenalidomide;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Condition:   Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone (or equivalent)
    Sponsors:   Janssen Research & Development, LLC;   Pharmacyclics
    Recruiting - verified April 2014

  • Condition:   Hematological Malignancy
    Interventions:   Drug: Cohort 1-Bortezomib (Velcade ®);   Drug: Cohort 2-Bortezomib (Velcade ®);   Drug: Cohort 3-Bortezomib (Velcade ®)
    Sponsors:   Spectrum Health Hospitals;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified October 2013

  • Condition:   Her2-Positive Breast Cancer
    Interventions:   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: 5-fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
    Sponsors:   Yale University;   Lajos Pusztai;   Genentech
    Recruiting - verified September 2013

  • Conditions:   Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
    Sponsors:   University of Iowa;   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Conditions:   Sickle Cell Disease;   Hemoglobinopathies
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide (CTX);   Drug: Mesna;   Drug: Sirolimus;   Drug: Mycophenolate mofetil (MMF);   Procedure: Bone marrow transplantation;   Radiation: Total body irradiation
    Sponsor:   Vanderbilt-Ingram Cancer Center
    Recruiting - verified November 2013

  • Conditions:   Crohn's Disease;   Crohn Disease
    Intervention:   Drug: High-dose Cyclophosphamide
    Sponsor:   Johns Hopkins University
    Not yet recruiting - verified May 2013

  • Condition:   Metastatic Melanoma
    Intervention:   Drug: Cyclophosphamide and Interleukin 2
    Sponsor:   Western Regional Medical Center
    Recruiting - verified January 2014

  • Condition:   Peripheral T-cell Lymphoma
    Interventions:   Drug: Belinostat;   Drug: CHOP
    Sponsor:   Spectrum Pharmaceuticals, Inc
    Recruiting - verified January 2014

  • Conditions:   Diffuse Large Cell Lymphoma;   Burkitt's Lymphoma;   High Grade B-cell Lymphoma
    Interventions:   Drug: Rituximab;   Drug: IT Cytarabine
    Sponsor:   New York Medical College
    Recruiting - verified February 2014

  • Condition:   Juvenile Myelomonocytic Leukemia
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: melphalan;   Drug: fludarabine phosphate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Veliparib
    Sponsors:   Thomas Jefferson University;   Susan G. Komen Breast Cancer Foundation
    Recruiting - verified January 2014

  • Conditions:   Childhood Cerebral Adrenoleukodystrophy;   (X-linked Adrenoleukodystrophy Cerebral Childhood)
    Interventions:   Genetic: Lenti-D Drug Product;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Filgrastim
    Sponsor:   bluebird bio
    Recruiting - verified April 2014

  • Conditions:   Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Tumor Infiltrating Lymphocytes
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Biological: therapeutic tumor infiltrating lymphocytes;   Biological: aldesleukin;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Radiation: Total Lymphoid Irradiation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Melphalan;   Biological: HPC,A Infusion;   Biological: TC-NK Infusion;   Biological: G-CSF;   Drug: Mesna;   Device: CliniMACS;   Drug: sirolimus
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified April 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mastectomy;   Radiation: Radiation Therapy
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting - verified February 2014

  • Condition:   Retinoblastoma
    Interventions:   Drug: vincristine;   Drug: topotecan;   Drug: filgrastim;   Drug: PEG-filgrastim;   Drug: carboplatin;   Other: focal therapy;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: MESNA;   Drug: doxorubicin;   Procedure: enucleation;   Radiation: external beam radiation
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified December 2013

  • Condition:   Breast Neoplasms
    Interventions:   Drug: Doxorubicin;   Biological: Trastuzumab;   Drug: Cyclophosphamide;   Drug: Paclitaxel
    Sponsor:   Washington University School of Medicine
    Recruiting - verified January 2014

  • Conditions:   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
    Interventions:   Drug: brentuximab vedotin;   Drug: doxorubicin;   Drug: prednisone;   Drug: vincristine;   Drug: cyclophosphamide
    Sponsors:   Seattle Genetics, Inc.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2014

  • Condition:   Neuroblastoma
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Topotecan;   Drug: Vincristine;   Radiation: external beam radiation therapy;   Procedure: PBSC;   Procedure: ASCT: autologous stem cell transplant (busulfan, melphalan);   Drug: Busulfan;   Drug: Melphalan;   Drug: Mesna
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified February 2014

  • Conditions:   Burkitt Lymphoma;   Burkitt Leukemia;   Diffuse Large B Cell Lymphoma;   Post Transplant Lymphoproliferative Disorder;   Primary Mediastinal (Thymic) Large B-cell Lymphoma
    Interventions:   Drug: DA-EPOCH-R for BL and B-ALL;   Drug: Methotrexate;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: G-CSF;   Drug: DA-EPOCH-R for DLBCL, PTLD & PMBCL
    Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI);   Texas Children's Hospital
    Recruiting - verified October 2013

  • Condition:   T-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Etoposide;   Drug: Prednisone;   Drug: Filgrastim;   Drug: Plerixafor;   Procedure: Stem Cell Collection;   Drug: Palifermin;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Transplant
    Sponsors:   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center
    Recruiting - verified February 2014

  • Condition:   Melanoma
    Interventions:   Drug: Cytoxan;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Procedure: T cell Infusion;   Drug: IL-2;   Other: Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Not yet recruiting - verified December 2013

  • Condition:   Hematologic Malignancies
    Interventions:   Procedure: Haploidentical Transplant;   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide
    Sponsor:   University of Illinois at Chicago
    Recruiting - verified November 2013

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Velcade;   Drug: Cyclophosphamide;   Drug: Revlimid
    Sponsors:   Duke University;   Sascha Tuchman;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified January 2014

  • Condition:   Chronic Lymphocytic Leukemia (CLL)
    Intervention:   Drug: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
    Sponsors:   Hackensack University Medical Center;   Celgene Corporation
    Recruiting - verified February 2014

  • Condition:   Neutropenia
    Interventions:   Drug: HM10460A (45 μg/kg);   Drug: HM10460A (135 μg/kg);   Drug: HM10460A (270 μg/kg);   Drug: Pegfilgrastim 6mg
    Sponsor:   Spectrum Pharmaceuticals, Inc
    Recruiting - verified April 2014

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Procedure: Bone marrow transplant;   Drug: Decitabine;   Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Radiation: 12 Gy Total body radiation
    Sponsor:   University of Wisconsin, Madison
    Recruiting - verified June 2013

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Ipilimumab;   Procedure: Tumor Infiltrating Lymphocytes (TIL);   Drug: Administration of Lymphodepletion;   Drug: Cyclophosphamide as Part of Lymphodepletion;   Drug: Fludarabine as Part of Lymphodepletion;   Drug: High Dose IL-2;   Biological: Adoptive Cell Therapy with TIL
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Recruiting - verified January 2014

  • Conditions:   Recurrent Childhood Acute B-lymphoblastic Leukemia;   Recurrent Childhood B-lymphoblastic Lymphoma
    Interventions:   Drug: dexamethasone;   Drug: vincristine sulfate;   Biological: rituximab;   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: etoposide;   Biological: aldesleukin;   Drug: pegaspargase;   Drug: methotrexate;   Drug: mercaptopurine;   Drug: cytarabine;   Drug: mitoxantrone;   Drug: teniposide;   Drug: vinblastine;   Biological: natural killer cell infusion;   Other: laboratory biomarker analysis;   Drug: therapeutic hydrocortisone;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer
    Recruiting - verified April 2014

  • Condition:   Malignant Neoplasm
    Interventions:   Biological: aldesleukin;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL;   Biological: dendritic cell vaccine therapy;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography
    Sponsor:   Jonsson Comprehensive Cancer Center
    Recruiting - verified January 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia
    Interventions:   Procedure: ex vivo-expanded cord blood progenitor cell infusion;   Procedure: umbilical cord blood transplantation;   Procedure: double-unit umbilical cord blood transplantation;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Hydroxychloroquine;   Drug: Rapamycin
    Sponsor:   OHSU Knight Cancer Institute
    Recruiting - verified August 2013

  • Condition:   Prostate Cancer Adenocarcinoma in Situ
    Interventions:   Drug: degarelix acetate;   Drug: Cyclophosphamide;   Drug: GVAX
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified November 2013

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2014

  • Conditions:   Leukemia;   Myelodysplastic Syndrome;   Lymphoma
    Interventions:   Device: CliniMACS Fractionation system (Arm A);   Device: CliniMACS Fractionation system (Arm B)
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified January 2014

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Biological: allogeneic hematopoietic cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2013

  • Conditions:   Malignant Solid Tumor;   Childhood Solid Tumor
    Intervention:   Drug: Sirolimus, Cyclophosphamide, Topotecan
    Sponsors:   University of California, San Francisco;   Hyundai Hope on Wheels Foundation
    Recruiting - verified January 2014

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: nilotinib;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: methotrexate;   Drug: cytarabine;   Drug: prednisone;   Drug: mesna;   Drug: dexamethasone;   Drug: leucovorin calcium
    Sponsor:   Mayo Clinic
    Recruiting - verified April 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Academic Myeloma Consortium;   Onyx Pharmaceuticals
    Recruiting - verified September 2013

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: High Dose Interleukin-2 (IL-2);   Procedure: ACT with TIL Infusion;   Drug: Vemurafenib;   Drug: Lymphodepletion
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting - verified April 2014

  • Condition:   Relapsed or Refractory Systemic Light Chain Amyloidosis
    Interventions:   Drug: MLN9708;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified September 2013

  • Conditions:   Glioma;   Neuroectodermal Tumors, Primitive;   Wilms Tumor;   Rhabdomyosarcoma;   Sarcoma, Ewing;   Osteosarcoma;   Retinoblastoma
    Interventions:   Drug: Metronomic Cyclophosphamide;   Drug: Thalidomide
    Sponsor:   Washington University School of Medicine
    Recruiting - verified February 2014

  • Conditions:   Advanced Cancers;   Leukemia
    Interventions:   Procedure: Leukapheresis;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: T-cell Infusion
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2014

  • Conditions:   Severe Combined Immunodeficiency;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   MHC Class II Deficiency;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Combined Immune Deficiencies;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Busulfan;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified October 2013

  • Condition:   Lupus Nephritis
    Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
    Sponsors:   GlaxoSmithKline;   Human Genome Sciences Inc., a GSK Company
    Recruiting - verified April 2014

  • Condition:   Systemic Lupus Erythematosus
    Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
    Sponsors:   GlaxoSmithKline;   Human Genome Sciences Inc., a GSK Company
    Recruiting - verified March 2014

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelocytic Leukemia;   Chronic Myelocytic Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Hodgkin or Non-Hodgkin Lymphoma
    Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: busulfan;   Drug: Plerixafor;   Drug: cyclophosphamide;   Drug: antithymocyte globulin (rabbit);   Biological: stem cells;   Drug: Tacrolimus;   Drug: mycophenolate mofetil
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified February 2014

  • Conditions:   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Drug: crizotinib;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: questionnaire administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   B-cell Childhood Acute Lymphoblastic Leukemia;   Childhood Diffuse Large Cell Lymphoma;   L3 Childhood Acute Lymphoblastic Leukemia;   Stage III Childhood Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Biological: rituximab;   Drug: prednisone;   Drug: etoposide;   Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: leucovorin calcium;   Drug: therapeutic hydrocortisone
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Eribulin;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsors:   M.D. Anderson Cancer Center;   Eisai Inc.
    Recruiting - verified April 2014

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine;   Radiation: Stereotactic Body Radiation (SBRT);   Drug: FOLFIRINOX
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified March 2014

  • Conditions:   Metastatic Cancer;   Melanoma
    Interventions:   Drug: Vemurafenib;   Drug: Young TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Conditions:   Head and Neck Cancer;   Head and Neck Squamous Cell Carcinoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cetuximab
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified October 2013

  • Conditions:   Metastatic Cancer;   Pancreatic Cancer;   Mesothelioma;   Ovarian Cancer;   Lung Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Aldesleukin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Condition:   Neuroblastoma
    Interventions:   Biological: Humanized anti-GD2 antibody;   Drug: Chemotherapy;   Other: Cytokines;   Biological: Natural killer cells
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified January 2014

  • Condition:   Crohn Disease
    Interventions:   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: tacrolimus;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Drug: fludarabine phosphate;   Procedure: allogeneic bone marrow transplantation;   Drug: mycophenolic acid;   Drug: mycophenolate mofetil
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Institutes of Health (NIH)
    Recruiting - verified November 2013

  • Conditions:   Malignant Solid Tumour;   Breast Cancer Nos Metastatic Recurrent;   Neuropathy
    Intervention:   Drug: Eribulin in Combination w/ Cyclophosphamide
    Sponsors:   University of California, San Francisco;   Eisai Inc.
    Recruiting - verified July 2013

  • Conditions:   Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Docetaxel;   Biological: HER2Bi-armed activated T cells;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified September 2013

  • Condition:   HIV
    Interventions:   Genetic: SB-728-T;   Genetic: SB-728-T;   Genetic: SB-728-T
    Sponsor:   Sangamo Biosciences
    Recruiting - verified February 2014

  • Conditions:   Breast Cancer;   Obesity
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsors:   Texas Tech University Health Sciences Center;   University of Texas
    Recruiting - verified January 2014

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Fox Chase Cancer Center;   Genentech
    Not yet recruiting - verified March 2014

  • Conditions:   Hematologic Malignancy;   Leukemia;   Acute Lymphoblastic Leukemia;   ALL;   Acute Myelogenous Leukemia;   AML;   Chronic Lymphocytic Leukemia;   CLL;   Lymphoma;   Hodgkin's Lymphoma;   Non-hodgkin's Lymphoma;   Myeloma
    Interventions:   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil (MMF);   Biological: Hematopoietic Stem Cell Transplant (HSCT)
    Sponsor:   Thomas Jefferson University
    Recruiting - verified February 2014

  • Condition:   Locally Advanced HER2-Negative Breast Cancer
    Interventions:   Drug: Eribulin Mesylate;   Drug: Cyclophosphamide;   Drug: Docetaxel
    Sponsors:   SCRI Development Innovations, LLC;   Eisai Inc.
    Recruiting - verified December 2013

  • Condition:   Breast Cancer
    Interventions:   Drug: TAC chemotherapy;   Drug: TC chemotherapy;   Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy;   Drug: TCH chemotherapy
    Sponsors:   Agendia;   University of South Florida;   University of Miami
    Recruiting - verified December 2013

  • Conditions:   Neuroblastoma;   Sarcoma
    Intervention:   Drug: Cyclophosphamide, Topotecan, and Bevacizumab
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Genentech;   Children's Mercy Hospital Kansas City;   Penn State University;   University of Colorado Health Sciences Center and The Children's Hospital;   Sidney Kimmel Comprehensive Cancer Center;   Phoenix Children's Hospital Center for Cancer & Blood Disorders;   Alberta Children's Hospital;   MD Anderson Cancer Center Orlando;   M.D. Anderson Cancer Center
    Recruiting - verified March 2014

  • Conditions:   Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Biological: ofatumumab;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: cytarabine;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: methotrexate;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   National Comprehensive Cancer Network;   GlaxoSmithKline
    Recruiting - verified February 2014

  • Condition:   Mantle Cell Lymphoma
    Intervention:   Other: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   GlaxoSmithKline
    Recruiting - verified March 2014

  • Condition:   HPV-related Head and Neck Cancer
    Intervention:   Biological: pNGVL-4a-CRT/E7 (detox) DNA vaccine
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Institute of Dental and Craniofacial Research (NIDCR);   Ichor Medical Systems Incorporated
    Recruiting - verified January 2014

  • Conditions:   Adult Liposarcoma;   Adult Synovial Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Drug: cyclophosphamide;   Biological: NY-ESO-1-specific T cells;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors;   Cancer of the Breast;   Neoplasms, Breast;   Tumors, Breast
    Interventions:   Drug: Eribulin;   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsors:   Emory University;   Eisai Inc.
    Recruiting - verified November 2013

  • Condition:   Sickle Cell Disease
    Intervention:   Drug: CD34 selected T-cell depleted allogeneic SCT
    Sponsors:   New York Medical College;   Children's Hospital & Research Center Oakland;   Medical College of Wisconsin;   Washington University;   Tufts Medical Center;   University of California, San Francisco;   University of California, Los Angeles;   Miltenyi Biotec GmbH
    Recruiting - verified March 2014

  • Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Malignant Glioma;   Glioblastoma;   Brain Cancer
    Interventions:   Genetic: Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Condition:   Scleroderma
    Interventions:   Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
    Sponsor:   Northwestern University
    Recruiting - verified February 2014

  • Condition:   Pleuropulmonary Blastoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Doxorubicin
    Sponsor:   Children's Hospitals and Clinics of Minnesota
    Recruiting - verified August 2013

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Velcade;   Drug: Chloroquine
    Sponsors:   New York University School of Medicine;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified December 2013

  • Condition:   Lymphoblastic Lymphoma
    Interventions:   Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine;   Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine;   Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine;   Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide;   Drug: Intrathecal chemotherapy
    Sponsors:   St. Jude Children's Research Hospital;   National University, Singapore
    Recruiting - verified November 2013

  • Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: vincristine sulfate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Neurotoxicity;   Pain;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Therapy-related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: clofarabine;   Drug: doxorubicin hydrochloride;   Drug: hydrocortisone sodium succinate;   Radiation: selective external radiation therapy;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: thioguanine;   Drug: etoposide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Thomas Jefferson University
    Recruiting - verified March 2014

  • Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Preparative Regimen;   Biological: Intravenous Recombinant Human IL-15 (rhIL-15)
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2013

  • Conditions:   Light Chain Deposition Disease (LCDD or MIDD);   Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD);   Monoclonal Immunoglobulin Deposition Disease (MIDD);   Amyloidosis
    Intervention:   Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2014

  • Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Inotuzumab Ozogamycin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Pegfilgrastim;   Drug: Methotrexate;   Drug: Ara-C
    Sponsors:   M.D. Anderson Cancer Center;   Pfizer
    Recruiting - verified April 2014

  • Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor Infiltrating Lymphocytes;   Drug: IL-15
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Preparative Regimen;   Biological: NK Cell Product;   Drug: Interleukin-2;   Biological: Donor CD34+ Cells;   Biological: Anti-thymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2013

  • Condition:   Chemotherapy-induced Nausea and Vomiting
    Intervention:   Drug: Palonosetron, ondansetron, dexamethasone
    Sponsors:   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
    Recruiting - verified October 2013

  • Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ofatumumab;   Drug: Methotrexate;   Drug: Cytarabine
    Sponsors:   M.D. Anderson Cancer Center;   GlaxoSmithKline
    Recruiting - verified April 2014

  • Condition:   Mesothelioma
    Interventions:   Drug: Pentostatin;   Drug: Cyclophosphamide;   Drug: SS1P
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Genetic: T-Cell Infusion;   Procedure: Cord Blood Infusion
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified January 2014

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: veliparib;   Drug: cyclophosphamide;   Other: placebo;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Conditions:   Sickle Cell Anemia;   Sickle Cell-hemoglobin C Disease;   Sickle Cell-β0-thalassemia
    Interventions:   Drug: Fludarabine;   Drug: Cytarabine;   Device: Cellular Infusions;   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Rituximab;   Procedure: Plasmapheresis
    Sponsors:   Thomas Jefferson University;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified February 2014

  • Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Thiotepa;   Genetic: Hematopoietic stem cell transplantation
    Sponsor:   Thomas Jefferson University
    Recruiting - verified November 2013

  • Conditions:   Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancy
    Interventions:   Biological: Epigenetically Modified Autologous Tumor;   Drug: Cyclophosphamide;   Drug: Celecoxib
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified October 2013

  • Conditions:   Hodgkin's Lymphoma;   Leukemia;   Myelodysplastic Syndrome(MDS);   Multiple Myeloma;   Non Hodgkin's Lymphoma
    Intervention:   Procedure: Bone Marrow Transplant
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified March 2014

  • Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome RAEB 1
    Interventions:   Drug: Lupron;   Drug: 18F FLT;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: Total Body Irradiation
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified October 2013

  • Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: everolimus;   Drug: prednisone;   Drug: vincristine sulfate
    Sponsors:   Alliance for Clinical Trials in Oncology;   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified July 2013

  • Conditions:   Chronic Leukemia;   Acute Leukemia;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Myelodysplastic Syndrome
    Intervention:   Procedure: Peripheral Blood Stem Cell Transplant
    Sponsors:   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
    Recruiting - verified October 2013

  • Conditions:   Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Syndromes;   Chronic Myelogenous Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Large Granulocytic Leukemia
    Intervention:   Procedure: Allogeneic transplantation
    Sponsor:   Scripps Health
    Recruiting - verified December 2013

  • Conditions:   Hematologic Malignancies;   Disorder Related to Transplantation;   Hematopoietic Malignancy
    Intervention:   Genetic: Preparative Regimen
    Sponsors:   St. Jude Children's Research Hospital;   The Hartwell Foundation;   Assisi Foundation
    Recruiting - verified March 2014

  • Condition:   Leukemia
    Interventions:   Drug: Rituximab;   Drug: Imatinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Mesna;   Drug: VSLI;   Drug: Solu-Medrol;   Drug: Methotrexate;   Drug: Ara-C;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Dexamethasone
    Sponsors:   M.D. Anderson Cancer Center;   Spectrum Pharmaceuticals, Inc
    Recruiting - verified December 2013

  • Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young Tumor Infiltrating Lymphocytes;   Procedure: 1200 Gy Irradiation
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified September 2013

  • Conditions:   Ovarian Carcinoma;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Biological: OC-DC vaccine;   Drug: Bevacizumab;   Drug: cyclophosphamide 300 mg/m2/d for 3 days;   Drug: fludarabine 30 mg/m2/d for 3 days;   Drug: ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified July 2013

  • Conditions:   Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancies
    Intervention:   Biological: Allogenic Tumor Cell Vaccine (K562)
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified July 2013

  • Condition:   Breast Cancer
    Interventions:   Drug: MM-302 Monotherapy;   Drug: MM-302 in combination with trastuzumab;   Drug: MM-302 in combination with trastuzumab q3w;   Drug: MM-302 in combination with trastuzumab and cyclophosphamide
    Sponsor:   Merrimack Pharmaceuticals
    Recruiting - verified February 2014

  • Conditions:   Leukemia;   Lymphoma;   Neuroblastoma;   Sarcoma;   Desmoplastic Small Round Cell Tumor
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Prednisone;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Filgrastim;   Biological: NK-DLI Infusions
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Condition:   Lymphoma, B-Cell
    Interventions:   Drug: RO5072759;   Drug: rituximab [MabThera/Rituxan];   Drug: CHOP chemotherapy
    Sponsors:   Hoffmann-La Roche;   Fondazione Italiana Linfomi ONLUS
    Recruiting - verified April 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Condition:   Transplant-Related Cancer
    Interventions:   Biological: Hepatitis A;   Biological: PCV 13
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Squamous Cell Carcinoma of the Oral Cavity;   Squamous Cell Carcinoma of the Soft Palate
    Interventions:   Biological: LI plus CIZ;   Other: Standard of Care (SOC);   Biological: LI + SOC
    Sponsors:   CEL-SCI Corporation;   Teva Pharmaceutical Industries;   Orient Europharma Co., Ltd.
    Recruiting - verified March 2014

  • Conditions:   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: alemtuzumab;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: fludarabine phosphate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Drug: dexamethasone;   Drug: cyclophosphamide;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: tacrolimus;   Drug: etoposide phosphate;   Drug: cytarabine;   Drug: mercaptopurine tablet;   Drug: vincristine sulfate;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Sapacitabine
    Sponsors:   M.D. Anderson Cancer Center;   Cyclacel Pharmaceuticals, Inc.
    Recruiting - verified November 2013

  • Conditions:   Lupus Erythematosus, Systemic;   Systemic Vasculitis;   Isolated Angiitis of Central Nervous System;   Lung Disease With Systemic Sclerosis;   Lung Disease Interstitial Diffuse
    Interventions:   Drug: depot leuprolide acetate 3.75 mg;   Drug: Placebo
    Sponsors:   University of Michigan;   Joseph Mccune;   National Institutes of Health (NIH)
    Recruiting - verified July 2013

  • Condition:   Myeloid Hematological Malignancies
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Cord Blood Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified March 2014

  • Conditions:   Metastatic Prostate Cancer;   Cancer of the Prostate;   Prostate Cancer
    Interventions:   Drug: Anti-OX40;   Radiation: Radiation;   Drug: Cyclophosphamide
    Sponsor:   Providence Health & Services
    Recruiting - verified December 2013

  • Conditions:   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Supratentorial Primitive Neuroectodermal Tumor;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Peripheral Primitive Neuroectodermal Tumor of the Kidney;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Metastatic Cancer;   Metastatic Melanoma;   Renal Cancer;   Colorectal Cancer;   Ovarian Cancer;   Lung Cancer
    Interventions:   Genetic: Anti-VEGFR2 CAR CD8 plus PBL;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Drug: Fludarabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified May 2013

  • Condition:   Hematologic Malignancies
    Interventions:   Other: Fludarabine, Cytoxan, TBI, Sirolimus + MMF;   Other: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified March 2014

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   AIDS-related Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   HIV Infection;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: vorinostat;   Drug: prednisone;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: etoposide;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   B-cell Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: thioguanine;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Relapsed Lymphoma;   B Cell Non-Hodgkin Lymphoma;   Refractory Lymphoma;   High Risk Chronic Lymphocytic Leukemia
    Interventions:   Drug: Rituximab;   Biological: Interleukin-2;   Biological: Natural killer cells;   Drug: Cyclophosphamide;   Drug: Methylprednisolone;   Drug: Fludarabine
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2013

  • Conditions:   Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: cisplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Radiation: iobenguane I 131;   Drug: busulfan;   Drug: melphalan;   Drug: isotretinoin
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   DOCK8 Deficiency
    Interventions:   Drug: Fludarabine;   Procedure: Allogeneic HSC transplant;   Drug: Cyclophosphamide;   Procedure: Total Body Irradiation (TBI)
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Conditions:   Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma;   Metastatic Esophageal
    Interventions:   Drug: CD8+ young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Condition:   Breast Cancer
    Interventions:   Biological: HER2Bi-armed activated T cells;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified September 2013

  • Conditions:   Small Lymphocytic Lymphoma;   CLL (Chronic Lymphocytic Leukemia)
    Interventions:   Drug: Fludarabine Phosphate;   Biological: Ofatumumab;   Drug: Cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI);   University of Virginia;   GlasoSmithKline
    Recruiting - verified March 2014

  • Conditions:   Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Thymoma;   Thymic Carcinoma
    Interventions:   Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified May 2013

  • Condition:   Prostate Cancer
    Interventions:   Biological: engineered autologous T cells;   Drug: cyclophosphamide
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Department of Defense
    Recruiting - verified October 2013

  • Condition:   Follicular Lymphoma
    Intervention:   Other: Combination of treatment modalities
    Sponsor:   St. Louis University
    Recruiting - verified July 2013

  • Condition:   Lymphoma
    Interventions:   Biological: bleomycin sulfate;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18;   Radiation: radiation therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified June 2013

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified March 2014

  • Conditions:   Stage I Breast Cancer;   Stage II Breast Cancer
    Interventions:   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: trastuzumab
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified May 2013

  • Conditions:   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma
    Interventions:   Drug: liposomal vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive
    Interventions:   Drug: rituximab;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone;   Drug: filgrastim
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified June 2013

  • Condition:   Fanconi Anemia
    Interventions:   Drug: Chemotherapy Preparative Regimen;   Biological: Miltenyi CliniMACS
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting - verified June 2013

  • Condition:   Pancreatic Cancer
    Intervention:   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified March 2014

  • Condition:   Mature B-Cell Lymphoma
    Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified February 2014

  • Conditions:   Mucopolysaccharidosis;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux-Lamy Syndrome;   Sly Syndrome;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Adrenoleukodystrophy (ALD);   Globoid Cell Leukodystrophy (GLD);   Krabbe Disease;   Metachromatic Leukodystrophy (MLD);   Sphingolipidoses;   Peroxisomal Disorders
    Interventions:   Drug: Campath-1H;   Drug: Cyclophosphamide;   Drug: Busulfan;   Procedure: Allogeneic stem cell transplantation;   Drug: Cyclosporine A;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified October 2013

  • Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors
    Interventions:   Drug: Standard Therapy;   Drug: AMG 386;   Drug: AMG 479 (Ganitumab) plus Metformin;   Drug: MK-2206 with or without Trastuzumab;   Drug: AMG 386 and Trastuzumab;   Drug: T-DM1 and Pertuzumab;   Drug: Pertuzumab and Trastuzumab
    Sponsor:   QuantumLeap Healthcare Collaborative
    Recruiting - verified February 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Panitumumab;   Drug: Nab-paclitaxel;   Drug: Carboplatin;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
    Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation;   Amgen
    Recruiting - verified March 2014

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Hematopoietic stem cell transplant;   Procedure: Mesenchymal stem cell transplant;   Radiation: Total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2013

  • Conditions:   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: filgrastim;   Procedure: peripheral blood stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation;   Procedure: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Conditions:   Thymoma;   Thymic Carcinoma.;   Clinical Masaoka Stage II-IVA
    Intervention:   Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Bristol-Myers Squibb;   M.D. Anderson Cancer Center;   City of Hope National Medical Center
    Recruiting - verified February 2014

  • Condition:   Breast Cancer
    Interventions:   Biological: HER2Bi-armed activated T cells;   Drug: Cyclophosphamide;   Other: Laboratory biomarker analysis
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified September 2013

  • Conditions:   Blood Stem Cell Transplant Failure;   Leukemia;   Hematologic Malignancies
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Procedure: Stem Cell Transplantation;   Drug: Thiotepa;   Drug: Tacrolimus;   Drug: Mycofenolate mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified February 2014

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Chronic Lymphocytic Leukemia;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous-allogeneic tandem hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Other: laboratory biomarker analysis;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Condition:   Breast Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Neratinib;   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Puma Biotechnology, Inc.
    Recruiting - verified April 2014

  • Condition:   Leukemia-Lymphoma, Adult T-Cell
    Interventions:   Drug: Bortezomib;   Drug: Etoposide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Cyclophosphamide;   Drug: Raltegravir
    Sponsor:   Washington University School of Medicine
    Recruiting - verified October 2013

  • Conditions:   Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.;   Device: CliniMACS device
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Children's Hospital Boston;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital and Health System Foundation, Wisconsin;   Rockefeller University;   Fred Hutchinson Cancer Research Center
    Recruiting - verified February 2014

  • Conditions:   Peripheral Blood Stem Cell Transplantation;   Anemia, Sickle Cell;   Graft-Versus-Host Disease;   Sirolimus (Rapamune );   Alemtuzumab (Campath )
    Interventions:   Procedure: PBMC Transplant;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune );   Drug: Cyclophosphamide (Cytoxan );   Procedure: Low Dose Irradiation
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified May 2013

  • Conditions:   Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
    Interventions:   Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   GlaxoSmithKline
    Recruiting - verified January 2014

  • Condition:   Breast Cancer
    Interventions:   Biological: allogeneic GM-CSF-secreting breast cancer vaccine;   Biological: trastuzumab;   Drug: cyclophosphamide
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   Leukemia;   Acute Lymphocytic Leukemia
    Interventions:   Drug: Everolimus (RAD001);   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Methotrexate;   Drug: Ara-C (Cytarabine);   Drug: Methylprednisone;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   Novartis
    Recruiting - verified November 2013

  • Condition:   Congenital Pediatric Disorders
    Interventions:   Drug: Busulfan;   Drug: Cytoxan;   Drug: Fludarabine;   Procedure: Cord Blood Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified March 2014

  • Conditions:   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Stage I Wilms Tumor;   Stage II Wilms Tumor;   Stage III Wilms Tumor;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
    Interventions:   Drug: doxorubicin hydrochloride;   Procedure: therapeutic conventional surgery;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: carboplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: nab-paclitaxel;   Drug: trastuzumab;   Drug: Doxorubicin;   Drug: cyclophosphamide
    Sponsors:   University of Kansas;   Celgene Corporation
    Recruiting - verified December 2013

  • Condition:   Breast Cancer
    Interventions:   Drug: Exemestane;   Drug: Docetaxel, cytoxan
    Sponsors:   Emory University;   Pfizer
    Recruiting - verified November 2013

  • Condition:   Adult T-Cell Leukemia (ATL)
    Interventions:   Drug: LMB-2;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: LMB-2, anti-Tac(Fv)-PE38
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Renal Cell Carcinoma;   Graft-Versus-Host Disease;   Engraftment Syndrome
    Interventions:   Drug: Pentostatin;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplant;   Procedure: Th2 Cell Transplantation;   Drug: Th2 Cells in Allogeneic HSCT
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Large Cell Lymphoma
    Interventions:   Genetic: Anti-CD19-CAR Transduced PBL;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Drug: vorinostat
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   Fanconi Anemia
    Intervention:   Device: CliniMACs device
    Sponsors:   Medical College of Wisconsin;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified October 2013

  • Condition:   Metastatic Melanoma
    Interventions:   Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells;   Drug: non-myeloablative conditioning chemotherapy
    Sponsors:   Jonsson Comprehensive Cancer Center;   California Institute of Technology;   University of Southern California;   University of Connecticut;   National Cancer Institute (NCI)
    Recruiting - verified August 2013

  • Condition:   Neuroblastoma
    Interventions:   Drug: Bevacizumab;   Drug: cyclophosphamide;   Drug: zoledronic acid
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Lymphoma;   Myeloma;   Leukemia
    Intervention:   Biological: Kappa CD28 T cells
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Houston Methodist Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified March 2014

  • Condition:   Lymphoma
    Interventions:   Biological: G-CSF;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Leucovorin;   Drug: Mesna;   Drug: Methotrexate;   Drug: Vincristine
    Sponsor:   University of Miami Sylvester Comprehensive Cancer Center
    Recruiting - verified February 2014

  • Conditions:   Neuroblastoma;   Bone Marrow, Sympathetic Nervous System
    Intervention:   Drug: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified February 2014

  • Conditions:   Untreated Childhood Medulloblastoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: vorinostat;   Drug: isotretinoin;   Drug: vincristine sulfate;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: thiotepa;   Procedure: peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
    Interventions:   Drug: Daunorubicin;   Drug: Vincristine;   Drug: PEG-asparaginase;   Drug: Intrathecal Methotrexate;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Thioguanine
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified January 2014

  • Conditions:   Leukemia, Myeloid, Acute;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelocytic, Chronic
    Interventions:   Other: Allogeneic Lymphocytes;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Methylprednisolone;   Drug: Cyclosporine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified September 2013

  • Conditions:   Multiple Myeloma;   End Stage Renal Disease
    Interventions:   Drug: Cyclophosphamide, anti-thymocyte globulin;   Procedure: Kidney transplant;   Radiation: Thymic irradiation;   Procedure: Bone marrow transplant from a related donor
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified March 2014

  • Conditions:   Systemic Lupus Erythematosus;   Systemic Sclerosis
    Intervention:   Procedure: Nonmyeloablative allogeneic stem cell transplant
    Sponsor:   Duke University
    Recruiting - verified November 2013

  • Conditions:   Breast Neoplasms;   Breast Cancer;   Cancer of the Breast
    Interventions:   Drug: Docetaxel and Cytoxan;   Drug: Dexamethasone
    Sponsors:   Emory University;   Sanofi
    Recruiting - verified November 2013

  • Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Biological: emepepimut-S;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Radiation: radiation therapy
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified October 2012

  • Conditions:   Lymphoma;   Nonneoplastic Condition
    Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem cell transplant x 1 or x 2;   Drug: lenalidomide and dexamethasone
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Tufts Medical Center;   Lahey Clinic
    Recruiting - verified December 2013

  • Condition:   Opsoclonus-myoclonus Syndrome
    Intervention:  
    Sponsor:   National Pediatric Myoclonus Center
    Recruiting - verified January 2014

  • Conditions:   MDS;   Leukemias;   Lymphomas
    Intervention:   Drug: Drug: busulfan, Cyclophosphamide, Total Body Irradiation
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Otsuka Pharmaceutical Co., Ltd.;   National Center for Research Resources (NCRR)
    Recruiting - verified March 2014

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenström Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Biological: natural killer cell therapy
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Wayne D. Kuni and Joan E. Kuni Foundation
    Recruiting - verified January 2014

  • Condition:   Devic's Disease
    Intervention:   Procedure: Hematopoietic stem cell transplantation
    Sponsor:   Northwestern University
    Recruiting - verified February 2014

  • Condition:   Severe Osteopetrosis
    Interventions:   Procedure: Stem Cell Transplantation;   Drug: Conditioning for transplantation-donor graft;   Radiation: Total Lymphoid Irradiation;   Drug: Conditioning for cord blood transplant
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2013

  • Conditions:   Chronic Lymphocytic Leukemia;   Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified November 2013

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Estrogen Receptor-negative Breast Cancer;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HER2-negative Breast Cancer;   Intraocular Lymphoma;   Male Breast Cancer;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Progesterone Receptor-negative Breast Cancer;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Breast Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Breast Cancer;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IIIC Breast Cancer;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Breast Cancer;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
    Interventions:   Drug: veliparib;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma;   Chronic Myelogenous Leukemia
    Intervention:   Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified April 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified January 2014

  • Condition:   Pancreatic Cancer
    Interventions:   Biological: GVAX pancreatic cancer vaccine;   Drug: cyclophosphamide
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Anaplastic Large Cell Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Procedure: double-unit umbilical cord blood transplantation;   Procedure: umbilical cord blood transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Pompe Disease;   Glycogen Storage Disease Type II (GSD-II);   Glycogenesis 2 Acid Maltase Deficiency
    Interventions:   Biological: Myozyme (alglucosidase alfa);   Biological: Myozyme (alglucosidase alfa)
    Sponsors:   Sanofi;   Genzyme, a Sanofi Company
    Recruiting - verified March 2014

  • Conditions:   Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total marrow irradiation;   Biological: Granulocyte-colony stimulating factor;   Biological: Hematopoietic Stem Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2013

  • Condition:   Melanoma
    Interventions:   Drug: cyclophosphamide;   Biological: Mature dendritic cell vaccine
    Sponsor:   Washington University School of Medicine
    Recruiting - verified December 2013

  • Conditions:   Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis
    Interventions:   Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
    Sponsor:   New York Medical College
    Recruiting - verified October 2013

  • Condition:   Lymphoma
    Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Refractory Solid Tumors;   Leukemia
    Interventions:   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Cyclophosphamide
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified March 2014

  • Conditions:   Colorectal Cancer;   Metastatic Cancer
    Interventions:   Biological: GM-K562 cell vaccine;   Biological: allogeneic tumor cell vaccine;   Drug: cyclophosphamide;   Genetic: gene expression analysis;   Genetic: protein analysis;   Other: immunoenzyme technique;   Other: immunologic technique;   Other: laboratory biomarker analysis
    Sponsors:   National Cancer Institute (NCI);   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified July 2009

  • Conditions:   Leukemia, Myeloid, Acute;   Leukemia, Lymphocytic, Acute, T-Cell;   Juvenile Myelomonocytic Leukemia Lymphoblastic;   T-cell Lymphoblastic Lymphoma;   Myelodysplastic Syndrome
    Interventions:   Procedure: Haploidentical donor derived natural killer cell infusion;   Drug: Chemotherapy;   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   National Cancer Institute (NCI);   Assisi Foundation
    Recruiting - verified October 2013

  • Condition:   Leukemia
    Interventions:   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: bone marrow transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2014

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic stem cell transplantation;   Drug: methylprednisolone;   Drug: filgrastim;   Drug: cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2013

  • Conditions:   Systemic Scleroderma;   Severe Systemic Sclerosis
    Interventions:   Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified March 2014

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2014

  • Conditions:   Neuroblastoma;   Medulloblastoma
    Interventions:   Drug: Nifurtimox;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   Spectrum Health Hospitals;   Giselle Sholler;   Bayer
    Recruiting - verified February 2014

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: umbilical cord blood transplantation;   Drug: Allopurinol;   Drug: fludarabine phosphate;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Biological: Treg infusion;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2013

  • Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: Induction Chemotherapy;   Drug: Low-Risk Therapy;   Drug: High-Risk Therapy;   Drug: Intermediate-Risk Therapy
    Sponsors:   St. Jude Children's Research Hospital;   University of Florida
    Recruiting - verified November 2013

  • Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: allogeneic bone marrow transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Chronic Granulomatous Disease
    Interventions:   Drug: Busulfan;   Biological: alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: cyclosporine;   Procedure: stem cell infusion
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified March 2014

  • Condition:   Thalassemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Campath 1H;   Drug: Cyclophosphamide;   Drug: MESNA
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified April 2014

  • Conditions:   Sickle Cell Disease;   Hemoglobin SC
    Interventions:   Drug: Busulfan;   Biological: Campath 1H;   Drug: Cyclophosphamide and Mesna
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting - verified August 2013

  • Condition:   Anemia, Aplastic
    Intervention:   Drug: Cyclophosphamide,Campath IH and TBI
    Sponsor:   Mayo Clinic
    Recruiting - verified January 2014

  • Condition:   Lymphoma
    Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: gemcitabine hydrochloride;   Drug: ifosfamide;   Drug: mechlorethamine hydrochloride;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Drug: vinorelbine tartrate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Acute Undifferentiated Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: lestaurtinib;   Drug: cyclophosphamide;   Drug: pegaspargase;   Drug: prednisone;   Drug: methylprednisolone;   Drug: dexamethasone;   Drug: cytarabine;   Drug: methotrexate;   Biological: filgrastim;   Drug: leucovorin calcium;   Drug: etoposide;   Drug: mercaptopurine;   Drug: vincristine sulfate;   Drug: hydrocortisone sodium succinate;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Extraocular Retinoblastoma
    Interventions:   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Biological: filgrastim;   Drug: carboplatin;   Drug: vincristine sulfate;   Drug: thiotepa;   Radiation: radiation therapy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   Leukemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine;   Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
    Sponsors:   St. Jude Children's Research Hospital;   National Cancer Institute (NCI);   Enzon Pharmaceuticals, Inc.
    Recruiting - verified November 2013

  • Condition:   Leukemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: asparaginase;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: pegaspargase;   Drug: prednisolone;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation
    Sponsors:   Dutch Childhood Oncology Group;   BFM Germany;   CORS Monza Italy;   Associazione Italiana Ematologia Oncologia Pediatrica;   ANZCHOG Austria New Zealand;   BFM Austria;   CLCG France Belgium Portugal;   COALL Germany;   CPH, Czech republic;   DFCI consortium USA;   FRALLE France;   Hong Kong;   MD Anderson USA;   NOPHO Scandinavian countries;   PINDA, Chile;   PPLLSG Poland;   Seattle USA;   SJCRH USA;   UKCCSG United Kingdom
    Recruiting - verified February 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin;   Procedure: Definitive Surgery;   Radiation: Radiotherapy
    Sponsor:   Leo W. Jenkins Cancer Center
    Recruiting - verified August 2013

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Disease;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Biological: rituximab;   Drug: Methotrexate;   Drug: Sirolimus;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine sulfate;   Drug: Cytarabine;   Drug: Tacrolimus;   Biological: Alemtuzumab
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Breast Cancer;   Pregnancy
    Interventions:   Drug: 5-Fluorouracil;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2014

  • Conditions:   Leukemia;   Lymphoblastic Lymphoma;   Leukemia, Lymphoblastic, Acute
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Vincristine;   Drug: Nelarabine
    Sponsors:   M.D. Anderson Cancer Center;   GlaxoSmithKline
    Recruiting - verified March 2014

  • Conditions:   Myelodysplastic Syndrome;   Leukemia
    Interventions:   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Rituximab;   Other: ATG;   Drug: Cyclophosphamide;   Drug: Clofarabine;   Radiation: Total Body Irradiation (TBI);   Drug: Melphalan;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   ViaCell;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Sickle Cell Disease
    Interventions:   Biological: G-CSF;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Allogeneic bone marrow transplantation;   Radiation: total-body irradiation;   Drug: Levetiracetam
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Cyclophosphamide;   Drug: Carmustine;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Antithymocyte globulin;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: rituximab
    Sponsor:   Stanford University
    Recruiting - verified July 2013

  • Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
    Interventions:   Drug: Campath 1H;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Stem Cell Transplantation;   Drug: antithymocyte globulin;   Drug: Methylprednisolone
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Biological: MV-NIS;   Drug: cyclophosphamide;   Other: I-123 prior MV-NIS;   Other: I-123 post MV-NIS;   Drug: Liothyronine
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Vincristine;   Genetic: RNA-based gene array studies;   Genetic: Real time PCR gene expression studies;   Genetic: Tissue-array immunohistochemical studies;   Genetic: Immunoglobulin G Fc receptor genotypes determination
    Sponsor:   University of Miami Sylvester Comprehensive Cancer Center
    Recruiting - verified February 2014

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Myasthenia Gravis
    Intervention:   Biological: Hematopoietic Stem Cell Transplantation
    Sponsor:   Northwestern University
    Recruiting - verified February 2014

  • Conditions:   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: daunorubicin hydrochloride;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: mercaptopurine tablet;   Radiation: radiation therapy;   Drug: nelarabine;   Drug: doxorubicin hydrochloride;   Drug: asparaginase;   Drug: dexamethasone;   Drug: thioguanine;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Condition:   Nonneoplastic Condition
    Interventions:   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Condition:   Fanconi Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2013

  • Condition:   Lymphoma
    Interventions:   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: irradiation therapy;   Biological: G-CSF;   Drug: Cytarabine
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2013

  • Conditions:   Untreated Childhood Medulloblastoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: etoposide;   Drug: cyclophosphamide;   Drug: cisplatin;   Biological: filgrastim;   Drug: carboplatin;   Drug: thiotepa;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Anemia, Aplastic
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Recruiting - verified June 2013

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   MDS;   Refractory Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Multiple Myeloma;   Non-Hodgkin's Lymphoma;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2013

  • Conditions:   Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified October 2013

  • Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total-body irradiation;   Drug: methylprednisolone;   Drug: allopurinol;   Drug: filgrastim
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2013

  • Condition:   Melanoma
    Interventions:   Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T Cells;   Biological: Interleukin-2;   Drug: Mesna
    Sponsors:   M.D. Anderson Cancer Center;   Prometheus Laboratories;   Key Biologics, LLC
    Recruiting - verified April 2014

  • Condition:   Systemic Lupus Erythematosus
    Intervention:   Biological: Hematopoietic stem cell transplantation
    Sponsor:   Northwestern University
    Recruiting - verified February 2014

  • Condition:   MYOPATHY
    Intervention:   Biological: hematopoietic stem cell transplantation
    Sponsor:   Northwestern University
    Recruiting - verified February 2014

  • Condition:   Multiple Sclerosis
    Interventions:   Procedure: Hematopoietic Stem Cell Therapy;   Drug: Standard treatment with a conventional drug
    Sponsors:   Northwestern University;   Rush University Medical Center;   University of Sao Paulo;   Uppsala University;   Sheffield Teaching Hospitals NHS Foundation Trust
    Recruiting - verified February 2014

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2013

  • Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
    Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
    Sponsor:   University of Rochester
    Recruiting - verified October 2013

  • Conditions:   Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
    Interventions:   Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting - verified December 2013

  • Condition:   Breast Cancer
    Interventions:   Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
    Sponsors:   Baylor Breast Care Center;   Baylor College of Medicine
    Recruiting - verified September 2013

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2013

  • Conditions:   Sickle Cell Disease;   Thalassemia;   Severe Congenital Neutropenia;   Diamond-Blackfan Anemia;   Shwachman-Diamond Syndrome
    Interventions:   Drug: Busulfan, Fludarabine, ATG, TLI;   Drug: Busulfan, Cyclophosphamide, ATG, GCSF;   Drug: Campath, Fludarabine, Cyclophosphamide;   Radiation: Total Body Irradiation;   Procedure: Stem cell infusion
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Marrow Donor Program
    Recruiting - verified May 2013

  • Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2013

  • Conditions:   Leukemia, Myeloid, Chronic;   Lymphomas;   Multiple Myeloma;   Myelodysplastic Syndrome;   Leukemia, Lymphocytic, Acute;   Leukemia, Lymphocytic, Chronic;   AML
    Interventions:   Procedure: Donor Lymphocyte Infusion;   Drug: Induction Chemotherapy + DLI
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified October 2013

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplasia;   Chronic Myeloid Leukemia;   Histiocytosis
    Interventions:   Drug: Chemotherapy and antibodies;   Device: Miltenyi Biotec CliniMACS;   Procedure: Allogeneic stem cell transplantation
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting - verified January 2014

  • Condition:   Juvenile Myelomonocytic Leukemia
    Intervention:   Procedure: Stem Cell Transplant
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2014

  • Conditions:   Brain Tumor;   Central Nervous System Tumor
    Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Childhood Langerhans Cell Histiocytosis;   Fanconi Anemia;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methylprednisolone;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Milton S. Hershey Medical Center
    Recruiting - verified October 2008

  • Conditions:   Brain and Central Nervous System Tumors;   Thrombocytopenia
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Etoposide phosphate;   Drug: Etoposide;   Drug: Sodium thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified July 2013

  • Condition:   Focal Glomerulosclerosis
    Interventions:   Procedure: Plasma exchange;   Drug: Cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting - verified September 2013

  • Conditions:   AIDS Related Lymphoma;   HIV Infection
    Interventions:   Biological: Rituximab;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified October 2013

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Procedure: peripheral blood stem cell transplantation;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: cyclosporine;   Procedure: autologous hematopoietic stem cell transplantation;   Biological: therapeutic autologous lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
    Intervention:   Procedure: Stem cell transplantation
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified September 2013


PaidClinicalTrials.orgPaidClinicalTrials.org